GSK plc (GSK) announced that the European Medicines Agency (EMA) has accepted its marketing authorization application (MAA) seeking approval for the Blenrep (belantamab mafodotin) combination therapy to treat relapsed or refractory multiple myeloma (RRMM) for review.The MAA seeks the approval of Blenrep in combination with J&J’s (JNJ) Velcade (bortezomib) plus dexamethasone (BorDex) or Bristol Myers’ Pomalyst (pomalidomide) plus dexamethasone (PomDex) for the myeloma indication in the EU. Per GSK, the advis ...